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Regulation of the pause and elongation by ribonucleic acid
(RNA) polymerase II (Pol II) is used widely by metazoans to
attain the pattern of gene expression that is essential for optimal
cell growth/renewal, differentiation, and stress response.
Currently, much of what we know about Pol II elongation
control comes from pioneering studies of the HIV-1-encoded
transactivating (Tat) protein and its host cellular cofactors. The
interaction between the two fuels a powerful feedback circuit
that activates human immunodeficiency virus (HIV) tran-
scription and prevents the virus from entering latency. One of
the key Tat cofactors is the human positive transcription
elongation factor b (P-TEFb), which exists in a family of
complexes with distinct functions during Tat transactivation.
This article reviews recent progress in HIV transcription
research with an emphasis on the intricate control of the
various P-TEFb complexes, structural and functional insights
into their interactions with Tat, the multifaceted roles of
posttranslational modifications of Tat, and epigenetic control of
HIV chromatin in modulating Tat activity and HIV latency.
The knowledge from these studies will not only help the design
of better strategies to fight HIV infection and transcriptional
latency, but also advance the overall understanding of the
mechanism controlling transcriptional elongation in general.
2. INTRODUCTION
Transcription of the HIV-1 proviral deoxyribonucleic acid
(DNA) into messenger RNA (mRNA) is a critical step in the
viral life cycle, as the mRNA serves not only as the template for
the synthesis of all viral structural and accessory proteins but
also as the genome for the next generation of viral particles.
Upon reverse transcription of the viral RNA in CD4+ T cells or
macrophages, the resulting HIV proviral DNA must be
integrated into the human chromatin before it can be
transcribed by host RNA polymerase II (Pol II). For all simple
retroviruses, transcription is mediated exclusively by the host
Pol II transcriptional apparatus. However, for a complicated
retrovirus such as HIV, this process is additionally controlled by
the virus-encoded transcriptional transactivator Tat protein
(Figure 1). Without Tat, Pol II initiates transcription from the
HIV promoter efficiently but travels only a short distance on
the viral template, producing short abortive transcripts that do
not support viral replication.1 To overcome this restriction, Tat
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is employed by HIV to dramatically increase the processivity of
Pol II to produce the full-length viral transcripts (Figure 1).
Unlike most other transcriptional activators that target
specific DNA sequences located in promoters or enhancer
regions, HIV Tat stimulates Pol II elongation through
interaction with the transactivation response (TAR) RNA
element, a stem-loop structure located at the 5′ end of all
nascent viral transcripts and synthesized by Pol II right before
pausing (Figure 1). Tat binds mainly to the 3-nucleotide bulge
and its immediate surrounding sequences right below the 6-
nucleotide TAR apical loop (Figure 1). Although the loop
sequence contributes minimally to the binding of Tat to TAR
in vitro, it is absolutely required for Tat to transactivate HIV in
vivo,2 suggesting that the loop sequence might have other
important functions (see section 3, last paragraph).
Because Tat is produced from the same HIV mRNA whose
production it stimulates, it fuels a powerful feedback circuit that
can lead to rapid and robust HIV gene expression under
optimal conditions.3 However, when HIV transcription
initiation is restricted by epigenetic silencing or low activity/
levels of key transcriptional activators (e.g., NF-κB or Sp1) on
the viral long terminal repeat (LTR), Tat concentrations can
fall below threshold levels, leading to the establishment of HIV
latency.4 Conversely, even a small increase in Tat expression
can sometimes be enough to drive a provirus from its latent
state into productive replication.5 It is worth noting that the
origin of Tat could even be extracellular, as Tat is able to
traverse lipid membranes through its arginine-rich transduction
motif.6 As such, Tat secreted from productively infected cells
can act as a viral growth factor to target neighboring cells to
stimulate HIV replication and latency reactivation. All in all, the
highly sensitive and signal-amplification nature of the Tat-based
feedback circuit establishes this small HIV protein as a
molecular switch that determines the “on” and “off” states of
HIV replication.
It is worth noting that HIV Tat has long been used as a
model system for studying the factors and molecular
mechanism that govern Pol II transcriptional elongation in
general. Exactly 20 years after elongation was first recognized as
a major check point that controls HIV gene expression,1
analyses conducted in both Drosophila and human stem cells
revealed that a great number of cellular genes also employ the
same mechanism to control their transcription.7 These genes,
which are mostly involved in stress response, cell growth/
renewal, and cell differentiation, contain paused Pol II at their
promoter-proximal regions. It is generally believed that the de
novo recruitment of Pol II and assembly of a functional
preinitiation complex (PIC) are very time-consuming. Thus,
the paused Pol II at these gene promoters under resting,
unstimulated conditions enables highly sensitive, rapid, and
synchronous induction of transcription that is essential for
stress response, cell growth/renewal, and development.8
In this article, we review recent progress in our under-
standing of HIV transcriptional control with an emphasis on
the effects exerted by macromolecular assemblies containing
HIV Tat/TAR and the host cellular cofactors. This progress is
critical not only to ongoing efforts to eradicate HIV/AIDS
through reactivating and then eliminating latent HIV reservoirs
that are in a transcriptionally silent state, but also to the
elucidation of the general mechanism that controls transcrip-
tional elongation of numerous cellular genes.
3. P-TEFB IS A KEY HOST CELLULAR COFACTOR FOR
TAT ACTIVATION OF HIV TRANSCRIPTION
Although elongation is a major rate-limiting step during HIV
transcription and HIV employs its own Tat and TAR to
overcome this restriction, mounting evidence in the 1990s
suggested that the mere binding of Tat to TAR is not sufficient
to induce HIV transactivation and that specific host cellular
cofactors are required in this process.9 This notion was
supported by many observations, and an especially important
one in 1990 showed that mutations in the apical loop of TAR
strongly block Tat activation of HIV transcription but have no
obvious effect on Tat binding in vitro.10
The ensuing years saw many unsuccessful attempts to isolate
and identify the specific Tat cofactors. After numerous trials
and errors, a major breakthrough finally arrived in the late
1990s with the identification of the human positive tran-
scription elongation factor b (P-TEFb) as such a cofactor.11
These studies demonstrated unequivocally that the Tat−TAR−
P-TEFb interaction at the HIV promoter is absolutely essential
for efficient activation of viral transcription.
P-TEFb is composed of the cyclin-dependent kinase 9
(CDK9) and its regulatory partner cyclin T (CycT). Whereas
the 42-kDa isoform of CDK9, denoted as CDK9(42), is the
predominant form of CDK9 in many cell types, there is also a
55-kDa isoform, denoted as CDK9(55), which has a 117-residue
amino terminal extension missing in CDK9(42).
12 Similarly, in
addition to CycT1, minor CDK9-associated CycT2a and T2b
molecules also exist in many cell types.13 However, Tat does
not recognize CycT2a and T2b and can bind to CycT1 only
through a Tat:TAR recognition motif (TRM) located at the
carboxy-terminal edge of the cyclin domain in T1.14
Although P-TEFb is ubiquitously present in all cell types, in
CD4+ T lymphocytes and monocytes, which are highly relevant
for HIV infection and replication, the expression of CycT1 is
Figure 1. HIV-encoded Tat protein stimulates the production of full-
length viral transcripts through binding to the HIV TAR RNA stem-
loop structure. The genomic structure of the HIV-1 virus is shown
with the coding region for the two-exon form of Tat highlighted in
blue. Tat, in conjunction with other cellular cofactors (indicated by
question marks), binds to the TAR RNA structure that is formed at
the 5′ end of the nascent HIV transcript to stimulate the production of
the full-length HIV mRNA (i.e., transcriptional elongation) by Pol II.
TSS indicates the transcription start site.
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normally low and repressed at the level of protein synthesis.15
In fact, the limited supply of P-TEFb could be an important
contributing factor to viral latency in primary T cells.16
However, the induced activation of T cells or the differentiation
of monocyte into macrophages, which markedly enhances
permissiveness of these cells to HIV infection, has been shown
to increase the protein but not mRNA level of CycT1.15
Although the posttranscriptional mechanism restricting CycT1
production in resting CD4+ T cells is still unknown, a
microRNA-dependent mechanism involving miR-198 was
reported to repress CycT1 mRNA translation and HIV
replication in monocytes.17
P-TEFb functions by phosphorylating serine residues located
at the second position (Ser2) within the heptapeptide repeats
that constitute the C-terminal domain (CTD) of the largest
subunit of Pol II. The phosphorylated CTD functions as a
scaffold upon which various transcription and RNA processing
factors meet and operate. These factors collectively control the
elongation and termination phases of Pol II transcription and
also facilitate cotranscriptional processing of pre-mRNAs.18 In
addition to the Pol II CTD, two negative transcription
elongation factors, DSIF and NELF, are also phosphorylated
by P-TEFb. The phosphorylation antagonizes their inhibitory
actions, leading to the release of Pol II from promoter-proximal
pausing and transition into productive elongation.18
The identification of P-TEFb as a key host cofactor for Tat
transactivation has provided satisfactory explanations for a
number of long-standing observations in the HIV transcription
field. For example, compared to many other cellular and viral
gene promoters, transcription from the HIV LTR had long
been indicated as particularly sensitive to kinase inhibitors such
as DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) and
flavopiridol.19 The strong correlation detected between the
ability of these two drugs to inhibit CDK9’s kinase activity and
their suppression of Tat transactivation immediately reveals the
reason behind this high sensitivity.
Moreover, it has long been known that Tat acts in a species-
specific manner to efficiently transactivate the viral LTR in
many human and primate cell types but not in cells from other
species (e.g., yeast, Drosophila, and murine cells).20 After the
identification of a direct interaction between Tat and human
CycT1, it was revealed that the interaction requires zinc as well
as essential cysteine residues in both proteins.21 However,
murine CycT1 lacks a critical cysteine (C261 in human CycT1)
that is required for a stable interaction. The substitution of a
cysteine for tyrosine at this position in murine CycT1 restores
its zinc-dependent binding to Tat, as well as its ability to
support Tat transactivation.14,22
Finally, earlier studies showed that the defect in Tat
transactivation in murine cells is also at the level of TAR
RNA recognition23 and that a hypothetical cellular Tat cofactor
encoded by a gene on human chromosome 12 confers on Tat
the ability to activate HIV transcription in a TAR loop-
dependent manner.24 This is despite the observation that no
specific loop sequence is required for the Tat−TAR interaction
in vitro. After the identification of human CycT1 as a direct
binding partner of Tat, the discovery that the CycT1 gene
indeed maps to human chromosome 12 and that CycT1
touches the TAR loop and forms a stable ternary complex with
Tat and TAR with a stringent requirement for the wild-type
TAR loop sequence11b,20,25 provides the long-sought validation
of the earlier observations.
4. SEQUESTRATION OF P-TEFB IN CATALYTICALLY
INACTIVE 7SK SNRNP
As a general transcription factor, P-TEFb is required not only
for Tat activation of HIV transcription but also for efficient
expression of a vast array of cellular genes. As such, the
availability and activity of P-TEFb must be carefully controlled
to respond to changes in the global transcriptional demand.26
For most CDKs, which belong to an extensive family of protein
kinases that are studied mainly for their roles in regulating the
cell cycle, it is well-known that specific inhibitors are used to
regulate their kinase activities.27 Because CDK9 is a member of
this superfamily, it is not surprising that the CDK9−CycT1
heterodimer, which constitutes the core of P-TEFb, can also
exist in a form that lacks catalytic activity. However, the way P-
TEFb is inhibited involves a mechanism that is quite different
from those used for other CDKs.
What sets P-TEFb apart from other CDKs is the involvement
of a small noncoding RNA molecule, termed the 7SK small
nuclear ribonucleic acid (snRNA), in inhibiting CDK9’s kinase
activity. Affinity-purified as an associated factor of CDK9,28
7SK is an abundant small nuclear RNA of 331 nucleotides that
is transcribed by RNA Pol III. When P-TEFb is present in a
7SK snRNA-containing large complex (Figure 2), it displays
little kinase activity toward the CTD heptapeptide repeats of
RNA Pol II.28a Although the 7SK−P-TEFb interaction was
found to be necessary for CDK9’s inhibition, it was soon
discovered that 7SK snRNA alone is insufficient for this task
and that additional factor(s) existing in the large 7SK/P-TEFb-
containing complex, termed the 7SK small nuclear ribonucleic
particle (snRNP; Figure 2), must work together with the
snRNA to suppress CDK9’s catalytic activity.29
Indeed, nuclear protein HEXIM1 was subsequently identified
through affinity purification of P-TEFb-associated factors and
found to reside in 7SK snRNP.29 It efficiently inhibits P-TEFb’s
phosphorylation of the Pol II CTD on Ser2 only in the
presence of 7SK snRNA. This is because 7SK snRNA is
Figure 2. P-TEFb is sequestered in 7SK snRNP and released in
response to various signaling events. Under normal conditions, the
majority of nuclear P-TEFb is sequestered in 7SK snRNP, where P-
TEFb’s kinase activity is inhibited by HEXIM1 in a 7SK snRNA-
dependent fashion. The stability of 7SK RNA is maintained by
MePCE and LARP7, which bind to the 5′ and 3′ ends, respectively, of
7SK. When cells are subjected to the indicated treatments (highlighted
in red), various signal transduction pathways are turned on, leading to
changes in posttranslational modifications that include phosphor-
ylation and acetylation on the indicated 7SK snRNP subunits and
release of P-TEFb from 7SK snRNP.
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required to bridge the interaction of P-TEFb with the central
region in HEXIM1 that contains positively charged residues
reminiscent of the arginine-rich TAR RNA-binding motif in
HIV Tat.30 In addition to HEXIM1, a close homologue
denoted as HEXIM2 was also found in the inactive P-TEFb-
containing 7SK snRNP.31 Although these two HEXIM proteins
exhibit distinct expression patterns in many human tissues and
established cell lines, they have the potential to form stable
homo- and heterodimers in a small set of 7SK snRNPs that
display similar or highly related functions.31a,b Consistent with
this notion, in HEXIM1-knocked-down cells, HEXIM2 was
shown to functionally and quantitatively compensate for the
loss of HEXIM1 to maintain a constant level of 7SK snRNPs in
vivo.29a Despite the functional similarity between HEXIM1 and
HEXIM2, HEXIM1 has a unique N-terminal region that
exhibits self-regulatory activity,29a suggesting that these two
homologous proteins might be regulated differently through
their regions of unique sequences.
7SK snRNA is known to serve as a scaffold in maintaining
the overall stability of 7SK snRNP.32 Because of the stringent
demand on its integrity, the stability of this snRNA is ensured
by two additional 7SK snRNP components that bind to the 5′
and 3′ terminal regions of 7SK RNA (Figure 2). At the 3′ end,
the poly(U) sequence of the nascent 7SK snRNA is initially
protected by the Lupus antigen (La) protein during tran-
scription and then replaced by the more specific La-related
protein 7 (LARP7) after synthesis.32,33 LARP7 is a highly
specific and abundant partner of 7SK snRNA, as approximately
90% of the snRNA in cells is bound to and relies on LARP7 for
stability.33 Notably, LARP7 is frequently mutated in human
gastric, breast, and cervical cancers, largely due to microsatellite
instability-associated frame-shift mutations that result in C-
terminally truncated proteins with no ability to bind to 7SK
snRNA and sequester P-TEFb into 7SK snRNP.32a,34
Consistent with the tumor suppressor role of a Drosophila
homologue of LARP7, loss of LARP7 function in human breast
epithelial cells has been shown to disrupt epithelial differ-
entiation and cause P-TEFb-dependent malignant trans-
formation.32a
On the opposite end of 7SK snRNA, MePCE, an S-adenosyl
methionine-dependent methylphosphate capping enzyme, is
responsible for monomethylation of the 5′ triphosphate of 7SK
snRNA, which helps protect against cleavage by exonucleases
(Figure 2).32b,35 However, it appears that 7SK is capped by only
the LARP7-free MePCE, probably in a cotranscriptional
manner prior to its sequestration into 7SK snRNP.32b Once
inside the snRNP, MePCE exerts a capping-independent
function to promote the LARP7−7SK interaction. Thus,
MePCE and LARP7 act cooperatively to stabilize 7SK RNA
and maintain the integrity of 7SK snRNP, which sequesters P-
TEFb in an inactive form.32b
Recently, in vivo RNA−protein interaction assays provided
more details about the sequence and structural elements of
human 7SK snRNA that direct the assembly of the 7SK−
LARP7−MePCE core snRNP.36 Whereas MePCE was shown
to interact with the basal part of the 7SK 5′-hairpin (the so-
called 5′-terminal G1-U4/U106-G111 helix-tail motif), LARP7
was found to bind to the 3′-terminal hairpin and the following
poly(U) tail of 7SK. Furthermore, the direct 7SK−LARP7
binding was demonstrated to be a prerequisite for recruiting P-
TEFb into 7SK snRNP, indicating that, in addition to providing
stability for 7SK snRNA, LARP7 plays a more complex role in
7SK-mediated P-TEFb regulation than previously anticipated.36
5. SIGNAL-INDUCED DISRUPTION OF 7SK SNRNP TO
RELEASE P-TEFB FOR STIMULATION OF HIV AND
CELLULAR GENE TRANSCRIPTION
Depending on the cell types, from 50% to 95% of cellular P-
TEFb has been reported to reside in 7SK snRNP.28a,37 Because
of the sequestration of such high levels of P-TEFb, this complex
is believed to serve as the primary cellular reservoir of unused
P-TEFb.26c Although the kinase activity of CDK9 is suppressed
by HEXIM1/2 within 7SK snRNP, CDK9 becomes fully active
once released because it already has the phosphorylated Thr186
at the tip of the so-called T-loop (Figure 2) and is thus
suspended in a preactivation state even before the release.38
A variety of conditions that globally affect cell growth and
differentiation have been shown to cause P-TEFb to reversibly
associate with 7SK snRNP (Figure 2), and thus the level of the
complex is dynamically controlled in cells.39 First, exposure of
cells to various stress-inducing agents such as transcriptional
inhibitors and DNA-damaging agents (e.g., flavopiridol, DRB,
actinomycin D, staurosporine, camptothecin and UV irradi-
ation) leads to the rapid dissociation of 7SK snRNP and an
increase in the pool of active P-TEFb.38b,40 This process is
presumably responsible for promoting the expression of many
stress-responsive genes as part of the natural cellular response
to stress. In fact, several of these agents (e.g., DRB and UV) are
known to activate HIV transcription in a P-TEFb-dependent
manner.41
In addition to playing a key role in stress response, the signal-
induced release of active P-TEFb from 7SK snRNP also
contributes to activation of HIV and cellular gene transcription
under certain growth-promoting conditions (Figure 2). For
example, the engagement of the T cell antigen receptor (TCR)
or activation of T cells by phorbol esters has been shown to
cause the disruption of 7SK snRNP and liberation of P-TEFb
to increase HIV transcription and terminate viral latency.42
Moreover, conditions that induce cardiac hypertrophy also
dissociate 7SK snRNP to release P-TEFb, leading to a global
increase in cellular RNA and protein contents and the
enlargement of heart cells.43 Finally, the differentiation inducer
hexamethylene bisacetamide (HMBA) has been found to
induce a biphasic response in the cellular 7SK snRNP level in
murine erythroleukemia cells, with an initial and transient
disruption of 7SK snRNP that is followed by a permanent
increase in the levels of HEXIM1 and 7SK snRNP after a
prolonged treatment to induce terminal differentiation.39 Taken
together, these observations reveal a strong correlation between
signal-induced disruption of 7SK snRNP and the induction of
HIV and cellular gene transcription during stress responses and
cell proliferation.
As increasing numbers of agents and conditions that cause
the release of P-TEFb from 7SK snRNP have been identified,
the mechanisms and signaling pathways responsible for the
release have also gradually been revealed (Figure 2). For
example, in HeLa cells, because the phosphorylation of Thr186
in the CDK9 T-loop is important for P-TEFb’s sequestration
into 7SK snRNP,38b one model proposes that protein
phosphatases such as PP1α and PP2B are activated by
HMBA or UV irradiation through a calcium-dependent
signaling pathway and then act cooperatively to dephosphor-
ylate Thr186 to release P-TEFb, which is subsequently
rephosphorylated through a still-unknown mechanism to regain
activity.38a The CDK9 T-loop can also be dephosphorylated by
phosphatase PPM1A and, to a lesser extent, PPM1B, leading to
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repression of HIV transcription.44 However, it is unclear
whether the PPM1A-mediated dephosphorylation can occur in
the context of 7SK snRNP to cause the disruption.
In experiments conducted in Jurkat T cells, HMBA was
shown to activate the PI3K/Akt pathway, which, in turn,
induces phosphorylation of HEXIM1 on the conserved Thr270
and Ser278 in the CycT1-binding domain and concomitant
disruption of 7SK snRNP.45 In a separate study also performed
in Jurkat T cells, the ERK kinase but not the PI3K/Akt pathway
was indicated as important in the disruption of 7SK snRNP by
activated TCR.37 Reaching a different conclusion, a recent
report showed that protein kinase C (PKC) can phosphorylate
Ser158 in HEXIM1 in response to the engagement of TCR or
activation by phorbol esters.42a Once Ser158 is phosphorylated,
HEXIM1 neither binds to 7SK snRNA nor inhibits P-TEFb.
Finally, adding yet another twist, acetylation of CycT1 by the
acetyltransferease p300 was reported to liberate P-TEFb from
7SK snRNP, although this modification is apparently not
required for the release of P-TEFb as induced by DRB,
actinomycin D, or HMBA.46 Taken together, these observa-
tions suggest that multiple signaling pathways and mechanisms
exist to facilitate the dissociation of P-TEFb from 7SK snRNP
and that different agents, conditions, or cell types can employ
different pathways to achieve this goal. It will be interesting to
test whether any of these pathways can communicate and
coordinate their actions to increase the overall efficiency of 7SK
snRNP disruption.
6. TAT EXTRACTS P-TEFB FROM 7SK SNRNP
Extensive structural and functional analyses have so far revealed
several interesting similarities between the Tat−TAR−P-TEFb
complex and 7SK snRNP. First, the arginine-rich TAR-binding
motif in Tat is highly homologous to and functionally
interchangeable with a portion of the 7SK-binding motif in
HEXIM1.30a Second, the Tat-binding site in the TAR RNA is
structurally and functionally similar to a region in 7SK snRNA
that is recognized by HEXIM1.30b Third, a small region near
the cyclin box of CycT1 can be bound by either HEXIM1 or
Tat.29b,47 These observations raise the possibility that Tat can
take advantage of these similarities to directly extract P-TEFb
from 7SK snRNP.
Indeed, a number of in vitro and in vivo studies have shown
that Tat does exhibit such a capability (Figure 3).48 Likely
owing to this capability, a significant reduction in the level of
7SK snRNP and an increase in the Tat−P-TEFb interaction
have been observed in both human primary blood lymphocytes
and cultured cell lines that are infected with HIV.48b,49 From
the perspective of HIV, it makes perfect sense for Tat to
directly target 7SK snRNP to obtain P-TEFb for HIV
transactivation. This is because the snRNP not only sequesters
up to 95% of all P-TEFb in the cell and is thus the principal
source of unobligated P-TEFb, but also keeps P-TEFb in a
preactivated state that is marked by the phosphorylated CDK9
T-loop.38a
Although the ability of Tat to extract P-TEFb from 7SK
snRNP has been clearly demonstrated, the underlying
mechanism(s) for this extraction is less clear. It is possible
that Tat might combine several different methods to maximize
its chance for success. Based on the observations that the
cysteine-rich domain of Tat binds to CycT1 with an affinity
higher than that displayed by HEXIM1,48a,50 Tat has been
proposed to use this domain to outcompete HEXIM1 for
binding to CycT1. After P-TEFb is captured by Tat, a
concomitant conformational change in 7SK snRNA might
permit the ejection of HEXIM1 from the snRNP.51 Another
model proposes that the RNA-binding motif within the
arginine-rich domain of Tat is responsible for P-TEFb’s
extraction.30b The idea is that Tat can use this motif to interact
with the region of 7SK snRNA that is normally contacted by
HEXIM1, thus displacing HEXIM1 and forming a transitional
HEXIM1-free 7SK snRNP (Figure 3).30b After the synthesis of
HIV TAR RNA, Tat and P-TEFb could be transferred out of
this complex to form the Tat/TAR/P-TEFb-containing
complex on the viral LTR. Recently, Tatcom2, a novel Tat/
P-TEFb-containing complex that lacks HEXIM1 but contains
all of the other 7SK snRNP subunits, has been identified.52
Detected in cells lacking the TAR RNA, this complex appears
to fit the descriptions of a transitional complex that exists
between 7SK snRNP and the eventual Tat/TAR/P-TEFb-
containing complex (Figure 3).
The exact subnuclear location where Tat extracts P-TEFb
from 7SK snRNP has yet to be determined. Although the vast
majority of the snRNP appears to exist off the chromatin and
can be easily extracted from the nucleus,53 a small amount was
recently detected at the HIV promoter.54 This latter
observation led to the proposition that the Tat−P-TEFb
elongation complex is assembled de novo on the HIV template
through the Tat−TAR interaction with the concomitant release
of P-TEFb from 7SK snRNP.55 Finally, the process through
which Tat extracts P-TEFb from 7SK snRNP might also be
assisted by other cellular cofactors. For example, the interaction
of Tat with protein phosphatase PP1,56 which contributes to
stress-induced 7SK snRNP disruption through dephosphor-
ylation of Thr186 at the CDK9 T-loop,56 could conceivably
Figure 3. Tat induces transfer of P-TEFb from 7SK snRNP possibly
through Tatcom2 to the SEC, where P-TEFb cooperates with ELL2 to
synergistically activate HIV LTR transcription. Tat is known to target
7SK snRNP to capture P-TEFb and release HEXIM1. The Tatcom2
complex, whose composition is similar to that of 7SK snRNP except
for the substitution of HEXIM1 by Tat, could be a reaction
intermediate before the emergence of HIV TAR RNA. Once TAR is
produced, P-TEFb and Tat are transferred onto the TAR structure,
and through a still unknown mechanism, they nucleate the formation
of the multisubunit SEC. In addition to P-TEFb, which phosphorylates
the Pol II CTD and negative elongation factors NELF and DSIF to
antagonize their inhibitory effects, SEC also contains another well-
characterized elongation stimulatory factor ELL2, which directly
enhances the catalytic activity of Pol II. By acting on the same Pol II
enzyme, P-TEFb and ELL2 synergistically activate HIV transcription.
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help Tat in the extraction process. In agreement with this
notion, PP1 has been shown to play a positive role in Tat
transactivation and HIV replication.57
7. TAT ASSEMBLES SUPER ELONGATION COMPLEX
(SEC) TO ACTIVATE HIV TRANSCRIPTION
As discussed previously, Tat can cause the release of P-TEFb
from 7SK snRNP. However, it was unclear whether Tat delivers
P-TEFb alone or in combination with additional factors to the
HIV LTR to stimulate viral transcription. To answer this
question, sequential affinity purifications that target HA-tagged
Tat, Flag-tagged CDK9, and any protein(s) associated with
these two factors in a single complex were performed.58 This
procedure led to the identification of a set of chromosomal
translocation partners of the mixed lineage leukemia (MLL)
protein, including ELL2, AFF4, ENL, and AF9, all of which are
demonstrated transcription factors/cofactors, as novel compo-
nents of the Tat−P-TEFb complex (Figure 3). Notably, the
same set of factors plus several others (e.g., the AFF4
homologue AFF1, the ELL2 homologue ELL1, and compo-
nents of the polymerase-associated factor complex PAFc) were
also independently isolated through a similar affinity-
purification scheme that targets HIV Tat alone.52
Because the form of CDK9 present in 7SK snRNP has the
phosphorylated Thr186 at the tip of the T-loop,38 it is expected
to be catalytically active once captured by Tat from 7SK
snRNP. As such, it had long been thought that the Tat−P-
TEFb interaction alone is sufficient to activate HIV tran-
scription. The great surprise coming from the identification of
several novel partners of the Tat−P-TEFb complex is that Tat
recruits not only P-TEFb but also another well-characterized
elongation factor, ELL2 or -1 to the viral LTR (Figure 3). (Data
obtained in our laboratory suggest that Tat strongly prefers
ELL2 over ELL1; N. He and Q. Zhou, unpublished
observations.)
Unlike P-TEFb, which stimulates transcriptional elongation
by phosphorylating key target proteins (the Pol II CTD, DSIF,
and NELF), ELL2/1 directly increases the catalytic rate of Pol
II by keeping the 3′ end of the nascent mRNA properly aligned
with the catalytic center within the polymerase enzyme to
prevent Pol II backtracking.59 Thus, Tat is able to deliver P-
TEFb and ELL2/1, which belong to different classes of
elongation factors, within a single complex to the viral LTR,
where these two factors can act on the same paused Pol II to
synergistically stimulate elongation (Figure 3). This observation
has significantly expanded the conventional view of the
mechanism of Tat transactivation and also explains why Tat
is such a powerful transcriptional activator. Because of the
existence of at least two well-established elongation stimulatory
factors in a single complex, this novel multisubunit complex is
now called the super elongation complex (SEC; Figure 3).
Recent structural and functional analyses of the SEC reveal
that AFF1 and AFF4, which are likely present in separate but
closely related SECs,60 function as a central scaffold to mediate
the formation of the complexes.26b,58,61 Detailed mapping
studies indicate that AFF4 (likely also the homologous AFF1)
employs short hydrophobic regions along its structurally
disordered axis to directly bind to and recruit other factors
into an SEC.61 Direct binding partners CycT1, ELL1/2, and
ENL or AF9 act as bridging components that link this complex
to two major elongation factors, P-TEFb and PAFc. The unique
scaffolding properties of AFF4 thus allow dynamic and flexible
assembly of multiple elongation factors while connecting the
components not only to each other but also to a larger network
of transcriptional regulators.
For a powerful elongation factor complex such as an SEC, it
would be hard to imagine that it is used only by Tat to
stimulate HIV transcription. The fact that all SEC subunits
except P-TEFb have previously been reported as MLL fusion
partners implies an intimate relationship between the SEC and
leukemic pathogenesis. Indeed, at about the same time as the
SEC was identified as a cofactor and binding partner of HIV
Tat, independent biochemical purifications of several frequently
occurring MLL chimaeras such as MLL-AFF1 and MLL-ENL
and their interacting molecules have led to the isolation of the
same SEC that turns out to be essential for MLL-mediated
leukemogenesis.62 It is believed that this high-order P-TEFb-
containing complex, which is biochemically distinct from the
MLL histone methyltransferase complex, promotes uncon-
trolled transcriptional elongation of MLL target genes to induce
leukemic transformation.62
8. ELL2 STABILIZATION PROMOTES SEC FORMATION
AND HIV TRANSCRIPTION
The Tat−SEC interaction, which provides the basis for SEC’s
original identification, not only allows Tat to recruit the
complex to the HIV LTR to activate viral transcription, but also
promotes SEC formation by stabilizing ELL2, which is
otherwise a highly labile protein.58 Unlike all of the other
SEC subunits, including its close homologue ELL1, ELL2 is
stoichiometrically limiting and uniquely regulated at the level of
protein stability. Recently, the RING domain protein Siah1 was
identified as the specific E3 ubiquitin ligase for ELL2
polyubiquitination and proteasomal degradation.63 Depletion
of Siah1 was shown to promote the formation of SECs and
enhance SEC-dependent HIV transcription, whereas over-
expression of Siah1 resulted in the degradation of ELL2 and, to
a lesser degree, AFF1 and AFF4.63
Consistent with an earlier observation that the interaction of
ELL2 with the scaffolding protein AFF4 (likely also AFF1)
dramatically increases the former’s half-life,58 Siah1 cannot
access any ubiquitinate ELL2 that is bound to AFF4, although
at high concentrations, it also degrades AFF1/4 to destroy
existing SECs.63 Unlike AFF4, Tat does not appear to act by
inhibiting ELL2 polyubiquitination, and the exact mechanism
by which it stabilizes ELL2 remains elusive at this moment.
There exists a possibility that Tat affects a step downstream of
the Siah1-mediated ELL2 polyubiquitination to directly
suppress proteasomal degradation of ELL2. In agreement
with this idea, Tat has been shown to directly bind to the β
subunits of the constitutive 20S proteasome, thereby inhibiting
the proteolytic activity of the proteasome in cells.64
9. BRD4−P-TEFB INTERACTION AND ITS CONTROL
OF HIV TRANSCRIPTION AND LATENCY
Many cellular genes, especially those that function as primary
response genes in stimulus-responsive pathways, often contain
paused Pol II and negative elongation factors at their promoter-
proximal regions before full induction.65 It has been shown that
these genes employ the nuclear protein Brd4 as an adaptor to
recruit P-TEFb to their chromatin loci.65b,66 To these genes,
Brd4 serves as the cellular equivalent of HIV Tat to antagonize
the inhibitory actions of negative elongation factors and
promote Pol II transcriptional elongation in a P-TEFb-
dependent manner.
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As a member of the bromodomain and extraterminal domain
(BET) protein family, Brd4 has two N-terminal bromodomains
that bind to acetylated histones H3 and H4,67 a P-TEFb-
interaction domain (PID) at its C-terminus that interacts with
P-TEFb,68 and a central extraterminal (ET) domain that has
been implicated in the interaction with a number of other
proteins.69 Notably, Brd4 remains bound to the chromatin
throughout the mitosis.67a,70 As an epigenetic reader, it is thus
able to transmit epigenetic memory across cell divisions by
recruiting and depositing P-TEFb onto promoters of key
growth-promoting genes prior to the onset of G1.70,71 In
addition to exerting its gene-activating effect through
interaction with acetylated chromatin, Brd4 is also known to
bind to the mediator complex within the preinitiation complex
(PIC), which might further enhance its overall transcriptional
activity.66a,72
Just as Brd4 plays an important role in recruiting P-TEFb to
many cellular gene promoters to release Pol II from pausing, it
also produces a positive effect on basal, Tat-independent HIV
transcription, although the effect obtained with the stably
integrated proviral DNA is generally smaller than that obtained
with the transiently transfected HIV LTR reporter con-
struct,66a,72,73 which cannot assemble into a chromatin
template. Thus, the interaction of Brd4 with the mediator
complex but not acetyl histones might play an even more
prominent role in mediating basal HIV transcription.
In contrast to the stimulatory effect of Brd4 on basal, Tat-
independent HIV transcription, Brd4 has been demonstrated to
be a potent inhibitor of Tat transactivation.66a,68 This is because
Tat and Brd4 can directly compete with each other for binding
to P-TEFb and the Brd4−P-TEFb interaction precludes the
more efficient and highly specific recruitment of P-TEFb/SEC
to the viral LTR by Tat and TAR (Figure 4A).66a As a result of
this competition, overexpression of just the PID domain of
Brd4 has been shown to antagonize Tat-dependent HIV
transcription and latency reactivation.68
10. REACTIVATION OF HIV TRANSCRIPTION AND
LATENCY BY BET BROMODOMAIN INHIBITORS
Latent reservoirs of HIV are the principal impediment to
eradication of infection, as they harbor transcriptionally silent
proviruses that can evade immune surveillance and resume
replication once the Highly Active Antiretroviral Therapy
(HAART) is disrupted.74 Strategies, generally referred to as
“shock and kill”, are currently being developed to reactivate
latent HIV, which can then be cleared by HAART and the
immune system.75 In devising such strategies, focus has been
placed on finding specific and effective ways to reactivate latent
HIV without causing generalized T-cell activation. To this end,
several laboratories have recently reported that the BET
bromodomain inhibitors JQ1 and iBet151, which can
competitively bind to the Brd4 bromodomains and displace it
from chromatin, efficiently reactivate latent HIV in a variety of
cell-line-based latency models.76
In-depth analyses reveal that the mechanism of JQ1-inducted
HIV latency reactivation is mainly through antagonization of
Brd4’s inhibition of Tat transactivation (Figure 4B).73a,77 By
displacing Brd4 from the LTR region of HIV chromatin and
thereby decreasing Brd4’s local concentration at the promoter,
JQ1 significantly increases the association of P-TEFb/SEC with
Tat.73a,77 As a result of this enhanced association, more SECs
are recruited by Tat/TAR onto the viral LTR to promote HIV
transcriptional elongation (Figure 4B).73a Further confirming
the functional significance of the SEC in HIV latency
reactivation, the siRNA-mediated knockdown of the key SEC
component ELL2 significantly reduces JQ1’s activation of the
LTR.73a
Similarly to JQ1, stable ectopic expression of a CDK9 mutant
carrying the Ser175 to Ala mutation (S175A) in latently
infected cells has also been shown to induce a robust Tat-
dependent reactivation of the provirus.78 Although S175A
destroys CDK9 phosphorylation on Ser175 that is induced by
TCR or phorbol ester (PMA) signaling, it only slightly reduced
Figure 4. Brd4 is a potent suppressor of Tat transactivation, and BET
bromodomain inhibitor JQ1 efficiently antagonizes this suppressive
effect. (A) In the absence of JQ1, the promoter-bound Brd4 (by
interacting with acetylated histones or Ac) competitively blocks the
interaction between P-TEFb and Tat. Likewise, methylation of Tat by
SETDB1 and PRMT6 also prevents this interaction. Meanwhile, most
cellular P-TEFb is sequestered in the inactive 7SK snRNP. All of these
features inhibit the ability of Tat to form on the HIV TAR RNA a
functional SEC that is essential for activated viral transcription. (B)
JQ1 dissociates Brd4 from the HIV promoter and increases the local
concentration of active P-TEFb for Tat to assemble into the SEC for
efficient phosphorylation of the Pol II CTD, DSIF, and NELF and
activation of productive elongation. Additionally, JQ1 inhibits the
expressions of SETDB1 and PRMT6 while promoting the production
of SIRT1, which deacetylates Tat to enhance the Tat−P-TEFb
interaction. Finally, JQ1 also disrupts 7SK snRNP to release P-TEFb,
providing another source of P-TEFb for SEC assembly at the HIV
promoter.
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the Tat−P-TEFb interaction. In contrast, the binding of Brd4
to P-TEFb is completely blocked by this mutation.66a,78
Because Brd4 is unable to compete with Tat for binding to
CDK9 carrying S175A, just like JQ1, the mutation effectively
removes the inhibition by Brd4, thus allowing the Tat-mediated
HIV transactivation and latency activation to occur.
In addition to JQ1’s direct and prominent enhancement of
Tat transactivation, additional activities displayed by this
compound might also contribute to its stimulation of HIV
transcription. For example, JQ1 has been shown to partially and
transiently release P-TEFb from 7SK snRNP (Figure 4B),73a,79
which could be responsible for its weak activation of basal HIV
transcription in the absence of Tat.73a,77 Although this effect of
JQ1 is weaker than that on Tat transactivation, it might help
trigger the first few rounds of productive elongation to help
build up the cellular Tat level and establish a positive feedback
circuit. Another potentially beneficial effect caused by JQ1 is
the induction of posttranslational modifications of Tat (Figure
4B).76 This may be achieved through JQ1’s induction of the
expression of SIRT1, a deacetylase and positive regulator of
Tat, and down-regulation of the expression of methyltrans-
ferases SETDB1 and PRMT6, which are two negative
modifiers/regulators of Tat (see section 12, seventh paragraph).
However, it remains to be determined whether Tat indeed
undergoes the implicated changes in the modifications in JQ1-
treated cells and, if yes, whether these changes directly
contribute to the JQ1-induced HIV latency activation.
It should be pointed out that, in primary CD4+ T cells
derived from patients on long-term HAART, the JQ1-induced
latency reactivation is relatively inefficient and highly
heterogeneous.76,77 This is likely because JQ1 targets primarily
the Tat transactivation step, which depends exquisitely on the
availability of the Tat cofactor P-TEFb/SEC, and because the
level of the key SEC component P-TEFb is very low in resting
CD4+ T cells.17,80 However, because full latency activation
must rely on Tat and its interaction with the SEC, which is
strongly promoted by JQ1, future studies will be very
informative to reveal whether a cocktail of drugs that contains
JQ1 as a key component plus other classes of latency activators
can be used to efficiently reactivate HIV latency through
overcoming multiple restrictions in resting CD4+ T cells. As a
proof of concept of this idea, JQ1 was shown to synergize with
prostratin, another well-known latency activator that works by
enhancing loading of RNA Pol II onto the HIV promoter,
thereby promoting transcriptional initiation, to reactivate latent
HIV.73a This synergism is detected in both Jurkat T cell-based
HIV latency models as well as in pools of resting CD4+ T cells
isolated from HIV-infected, HAART-treated patients.73a,77
JQ1 has been proposed as an anticancer drug that works by
reducing the Brd4-dependent c-myc expression, leading to the
induction of differentiation and growth arrest of cancer cells
that are addicted to the c-myc oncogene.81 Consistent with its
general antigrowth property, JQ1 has been shown to potently
suppress T-cell proliferation with minimal cytotoxic effect.76
This inability to cause generalized T-cell activation, together
with its use of a largely Tat-specific mechanism in reactivating
latent HIV, make JQ1 and its derivatives attractive candidates
for implementing the “shock” phase of the shock-and-kill
strategy to reactivate latent HIV reservoirs for subsequent
eradication.75b
11. STRUCTURAL AND FUNCTIONAL
CHARACTERIZATION OF TAT INTERACTIONS
WITH ITS PARTNERS
The Tat gene has two exons, and the first one encoding amino
acid residues 1−72 is both necessary and sufficient for HIV
transactivation. Among the five conserved regions within the
first exon, the first three (acidic/proline-rich, cystein-rich/Zn
finger, and core) constitute the minimal transactivation domain
that is vital for the Tat−P-TEFb interaction. According to the
crystal structure of the Tat−P-TEFb complex solved by
Tahirov et al.,55 this 49-amino-acid (49-aa) minimal trans-
activation domain, which is the only well-resolved portion of
the 86-aa recombinant Tat protein in the crystal structure,
interacts extensively with residues located mainly in the cleft
between the two cyclin box repeats of CycT1 and also extends
to partially touch the CDK9 T-loop. Whereas an intramolecular
zinc finger coordinated by Cys22, Cys34, Cys37, and His33 is
clearly visible within the Tat structure, a proposed intermo-
lecular zinc finger involving Cys261 of CycT1 and Cys25,
Cys27, and Cys30 of Tat, which are not conserved in Tat
proteins from other species, has been questioned for its
physiological relevance.73b Nevertheless, as the interaction
surface between CDK9 and CycT1 is ∼40% smaller than those
in other CDK−cyclin pairs,82 the extensive Tat−P-TEFb
interaction with a surface area twice as large as the average
value for stable protein−protein interactions55,83 explains how
Tat stabilizes the P-TEFb complex.84
It is interesting to note that, when existing alone in solution
without any binding partners, Tat is highly flexible and has no
defined secondary structure along most of its sequence.85 Only
upon binding to P-TEFb does Tat obtain its defined
structure.55 In fact, Tat adopts a conformation that is highly
complementary to the surface of P-TEFb. In return, Tat also
induces significant conformational changes in P-TEFb,55,82
leading to the establishment of a more active kinase complex.84
As a key regulatory protein encoded by a small virus, the
flexibility of Tat and its dependence on host partners to adopt
defined structures can be advantageous in several respects. First,
they can allow Tat to interact with more than one host factor
complex and thus facilitate the transfer of Tat from one
complex (e.g., Tatcom252) to another (e.g., the SEC58) at
different stages of HIV transactivation. Second, they are
economical to the relatively small HIV genome, which does
not need to encode an exceptionally long polypeptide that
might be necessary to stabilize the Tat structure.86 Finally, they
afford Tat a relatively high tolerance to sequence variations (up
to 40%) without losing transactivation activity.85
As the Tat−P-TEFb complex is only a nonphysiological
subcomplex of the larger functional Tat−SEC assembly
recruited to the HIV promoter for transactivation, it is
important to determine how the interactions between P-
TEFb and other SEC subunits impact the Tat−P-TEFb
interaction. As an important step toward this goal, the crystal
structure of a tripartite complex containing the recognition
regions of P-TEFb and AFF4, which functions as a scaffold in
the SEC, was recently solved.87 AFF4 was shown to use the
Leu34−Ile66 segment to meander over the surface of CycT1
on the opposite side of the CDK9-binding site, thus making no
direct contact with CDK9 (Figure 5). Interface mutations were
found to reduce CycT1 binding and AFF4-dependent HIV
transcription. Although Tat is not present in the structure, a
unique intersubunit pocket created cooperatively by AFF4 and
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CycT1 would provide an excellent fit for Tat (Figure 5).
Consistent with this prediction, Tat was shown to significantly
increase the affinity of AFF4 for P-TEFb by more than 10-fold,
which could be the reason for Tat to recruit the whole SEC but
not P-TEFb alone to the viral LTR. Interestingly, one particular
residue in Tat that is predicted to directly contact AFF4 is
Lys28 (Figure 5), which was previously reported to be
important for the formation of the Tat−TAR−P-TEFb
complex.88 As Lys28 is strictly conserved and exquisitely
regulated by reversible acetylation,73b,89 it will be interesting to
investigate whether this residue plays a key role in Tat-
mediated recruitment of the SEC to TAR as well as termination
of the TAR-dependent phase of Tat transactivation (reviewed
in section 12, sixth paragraph).
At this point, none of the published structures of human P-
TEFb and P-TEFb-containing complexes contains the HIV
TAR RNA.55,82,87 Although the arginine-rich motif (ARM)
region of Tat was not visible in the solved Tat−P-TEFb
structure,55 it is safe to predict that this region will likely adopt
a well-defined conformation once bound to the recognition
region in TAR. Indeed, a recent crystal structure of the
tripartite ribonucleoprotein complex formed by EIAV Tat and
TAR and the corresponding equine CycT1 strongly supports
this notion.90 In this structure, both the C-terminal part of
EIAV Tat (amino acids 41−69) that encompasses the ARM as
well as the associated TAR RNA were resolved. Whereas the
core and the C-terminal hydrophobic regions of EIAV Tat wrap
around the surface of equine CycT1 at the first cyclin box
repeat, the ARM, which lies between the two Tat regions,
interacts with the major groove of TAR RNA. The interactions
are largely electrostatic in nature and involve the basic residues
in the Tat ARM and the negatively charged phosphate
backbone of TAR. These electrostatic interactions, although
not expected to afford high selectivity among the various TAR
species of different base pair compositions, can still be
modulated through reversible acetylation of specific lysine
residues in the ARM to alter its charge properties (reviewed in
section 12, third paragraph). Finally, in the tripartite structure
formed by EIAV Tat/TAR and equine CycT1, the TAR
displays a stable six-nucleotide hairpin-loop, with the fifth
nucleotide directly contacting CycT1, which contributes to the
specificity of the overall interaction.90
Although much progress has been made toward the
structural and functional characterization of the interactions
of Tat with a subset of its binding partners, the more
challenging and also urgent task remaining is to solve the
structures of several complete macromolecular assemblies, such
as 7SK snRNP, Tatcom2, and the Brd4−P-TEFb and Tat−
TAR−SEC complexes, that are essential for the proper function
of Tat. Obtaining such structures will provide unprecedented
insights into the molecular mechanisms by which Tat and its
cofactors activate HIV transcription. It might also reveal novel
druggable targets and assist the design of small-molecule
inhibitors that can specifically target the Tat-associated
transactivation machinery with minimal cytotoxic side effects.
12. POSTTRANSLATIONAL MODIFICATIONS OF TAT
AND THEIR EFFECTS ON HIV TRANSCRIPTION
Given its central role in HIV transactivation, it is not surprising
to see that the activity of Tat is elaborately controlled by
posttranslational modifications that include methylation,
acetylation, phosphorylation, and polyubiquitination (Figure
6). Most of these modifications are located in the ARM of Tat
and can influence the formation or disruption of the Tat−
TAR−SEC complex. Notably, many of these sites are targeted
by both the “writing” and “erasing” enzymes, which permit the
fine-tuning of Tat function during different phases of HIV
transactivation. Interestingly, many of the Tat modification
Figure 5. HIV Tat and SEC component AFF4 are predicted to make
direct contacts on CycT1. This superposition of the crystal structures
of the AFF4−P-TEFb complex and the Tat−P-TEFb complex using
the CycT1 subunit (yellow) shows the close proximity of AFF4 (blue)
and Tat (red). The resulting Tat−AFF4−P-TEFb complex model is
shown in two different orientations that are rotated by about 90°
(CDK9 is in gray). The side chains of Tat are from only those residues
that are known to have an effect on transcription when mutated and
that do not have any identified binding partner or structural function.
Lys28, which is well-known for its influence on complex stability upon
acetylation, is engaged in the AFF4 interaction in this model but
exposed to solvent in the Tat−P-TEFb complex. Arg49, which is the
last visible Tat residue in the structure, indicates where the RNA
binding domain will be located. (Figure courtesy of Ursula Schulze-
Gahmen and Tom Alber of UC Berkeley.)
Figure 6. Posttranslational modifications of Tat and their effects on
HIV transcription. The modifications (modified residues shown in
boxes) can be classified into two types based on their impact on Tat’s
transactivation activity: positive (green) and negative (red). The
physiological consequences of the modifications during different
phases of the HIV and Tat transactivation cycles are displayed in blue.
The black arrows accompanied by a plus (+) sign indicate that the
modifications promote the formation of the indicated complexes. Me1,
Me2, and Me3 denote mono-, di-, and trimethylation, respectively. Ac,
acetylation; Pi, phosphorylation; (Ub)n, polyubiquitination. The
amino acid sequence of the 86-aa form of HIV-1 Tat is shown at
the bottom with the modified residues indicated in boldface type and
their positions shown above and below the sequence.
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enzymes are also involved in histone modifications, thus linking
the control of Tat activity to the chromatin status of an
integrated HIV provirus.
The most heavily modified residue in Tat is Lys51 (Figure
6), which plays a central role in the interaction with HIV TAR
RNA.90 Monomethylation of Lys51 by SET7/9 (KMT7)
enhances Tat activity likely by strengthening the Tat−TAR
interaction.90,91 Because SET7/9 itself has been shown to bind
to TAR,91 its proximity to Tat might allow for efficient
methylation of Lys51 to facilitate the recruitment of the Tat−
SEC complex to the TAR. Interestingly, whereas monomethy-
lation of Lys51 is an activation marker for Tat, removing this
methyl group by the lysine-specific demethylase LSD1
(KDM1) and its cofactor CoREST is apparently also required
for the full transactivating function of Tat, as well as the
reactivation of latent HIV.92 To reconcile these seemingly
contradictory observations, it has been proposed that Tat
transactivation is actually composed of two distinctive phases,
namely, the TAR-dependent early phase and the subsequent
TAR-independent phase.73b In the TAR-dependent phase,
Lys51 is monomethylated by SET7/9 to facilitate the
recruitment of the Tat−SEC complex to the TAR RNA.
Subsequently, LSD1 and CoREST demethylate the same lysine
to facilitate the dissociation of the Tat−TAR−SEC complex
and prepare Tat for acetylation at Lys51, which are important
for the subsequent TAR-independent phase of Tat trans-
activation (Figure 6).73b During this second phase, Tat is
proposed to directly interact with Pol II93 and recruit the
histone acetyltransferase (HAT) PCAF and chromatin
remodeling complex PBAF to generate a further relaxed
chromatin environment in a TAR-independent manner. Thus,
Lys51 acts as a molecular switch, with its monomethylation
promoting the Tat−TAR−SEC formation and acetylation
enhancing the Tat−PBAF-PCAF assembly (Figure 6).
To efficiently disrupt the Tat−TAR−SEC complex, upon the
demethylation of Lys51, Lys51 and its neighboring Lys50 must
be acetylated by acetyltransferases p300/CBP (KAT3B) or
GCN5 (KAT2A) (Figure 6).89,94 The acetyl groups neutralize
the positive charges in the highly basic ARM to dissociate Tat
from TAR. This step is critical to terminate the TAR-dependent
phase and enable the transition into the TAR-independent
phase.95 Of note, Lys50 acetylation also facilitates the
recruitment of chromatin-modification transcriptional coactiva-
tors such as PCAF (KAT2B) and the SWI/SNF complex PBAF
onto Tat.96
Just as for the demethylation of Lys51, the deacetylation of
Lys50 by sirtuin 1 (SIRT1) is also required for the full
transactivating function of Tat.91 A possible reason for this
requirement is that the deacetylation happens toward the end
of productive transcription to recycle Tat back to the
unacetylated state so that it can bind to TAR/SEC again and
start a new round of transactivation.73b Paradoxically, the
overexpression of SIRT1 was found to significantly hinder Tat
transactivation in latently infected cells.97 This is probably
because the Tat level is very low at the beginning of latency
reactivation and too much SIRT1 activity will interfere with the
TAR-independent Tat transactivation step and disrupt the
establishment of the positive Tat feedback circuit that is critical
for latency reactivation.97
These observations concerning reversible modifications at
Lys50 and Lys51 indicate that the activity of Tat is elaborately
regulated by both writers and erasers of posttranslational
modification marks. The functions of individual modification
enzymes cannot be simply classified as positive or negative with
regard to the overall Tat transactivation and latency reactivation
process. Rather, they should be viewed as indispensible
components of a complete, interrelated regulatory network
(Figure 6) that exerts proper control of HIV transcription in
response to changing conditions and viral replication status
within an infected cell.
Similarly to Lys50 and Lys51, Lys28, which is located in the
cysteine-rich region of Tat, can also be acetylated. Catalyzed by
PCAF (KAT2B), the acetylation of Lys28 enhances the binding
of Tat to P-TEFb/SEC and TAR89,96a to promote Tat
transactivation. Unlike the deacetylation on Lys50, deacetyla-
tion on Lys28 by HDAC6, a class II HDAC also responsible for
deacetylating α-tubulin,98 inhibits Tat transactivation as it
destabilizes the Tat−TAR−P-TEFb/SEC complex.99 The
interaction between HDAC6 and Tat appears to depend on
microtubules,99 and the binding of Lys28-acetylated Tat to
tubulin/microtubules perturbs microtubule dynamics, leading
to apoptosis of T lymphocytes.100 Because HDAC6 can
suppress both Tat transactivation and Tat-induced apoptosis,
it might serve as a potent host cell antagonist of HIV/AIDS.
In addition to the already mentioned reversible modifica-
tions, Tat is also subject to posttranslational modifications for
which no erasers have been identified. These modifications
span across the entire length of Tat and include di-/
trimethylation, phosphorylation, and polyubiquitination. For
example, Lys50 and Lys51 can be di- or trimethylated by
SETDB1 (KMT1E).101 Likewise, the neighboring Arg52 and
Arg53 can also be methylated by another methyltransferase,
PRMT6 (Figure 6).102 There is currently no enzyme that can
erase these modifications. Located in the Tat ARM region,
these methylation events interfere with the formation of the
Tat−TAR−P-TEFb/SEC complex probably through steric
hindrance.90 Of note, the methylations on Arg52 and Arg53
have an additional role in increasing the stability of Tat,103
suggesting that they might serve to tag a stable pool of inactive
Tat in latently infected cells.
HIV Tat can also be phosphorylated by the PKR kinase and
the CDK2/cyclin E kinase complex.104 PKR phosphorylates
Ser62, Thr64, and Ser68, which results in faster and stronger
binding of Tat to TAR and promotes Tat transactivation.104a
CDK2/cyclin E phosphorylates two highly conserved Tat
residues Ser16 and Ser46, and this event is reported to be
important for the expression from a transiently transfected HIV
LTR-LacZ reporter construct and viral replication in a HeLa-
based proviral system.104b
Polyubiquitination is frequently used as a tag that marks a
protein for degradation by the proteasome. However, in the
case of Tat, this particular modification has been shown to
promote the transactivating function of Tat without inducing
Tat degradation.105 The polyubiquitination appears to be
catalyzed by the proto-oncoprotein Hdm2, which interacts with
Tat and functions as a specific E3 ligase to induce
ubiquitination on Lys71 (Figure 6). At this moment, the
mechanism by which the polyubiquitinated Tat enhances HIV
transactivation is unclear. By targeting and dissociating the 26S
proteasome, Tat has been shown to activate HIV transcription
in a manner that does not depend on the proteolytic activity of
the proteasome.106 It is tempting to speculate that the
polyubiquitinated Tat in association with key proteasomal
components might play a key role in this process.
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13. EPIGENETIC REGULATION OF HIV
TRANSCRIPTION
In addition to the central role that the Tat−TAR−SEC axis
plays in overcoming the restriction on Pol II elongation, HIV
transcription is also subjected to epigenetic regulation. The
types of regulation directly affect the compactness of the HIV
chromatin, thus altering the accessibility of a provirus to general
transcription factors/cofactors and transcriptional regulators,
which in turn determines whether the provirus enters the
repressive or active transcription state. In the context of HIV
transcription, the epigenetic regulation can be divided into two
categories: (1) covalent modifications that include histone
acetylation, histone methylation, and DNA methylation and (2)
chromatin remodeling that moves nucleosomes around relative
to key binding sites in a ATP-dependent manner. One
particular nucleosome called Nuc-1, which is located ∼50 bp
downstream of the HIV transcription start site (TSS), plays a
central role in blocking Pol II transcription of the
provirus.96c,107 Thus, most types of epigenetic regulation that
affect the transcriptional state of the HIV provirus frequently
target this nucleosome.
Histone deacetylation is known to induce the compact
chromatin structure that represses the recruitment and
assembly of active transcriptional machinery at the promoter.
In the case of HIV, two transcriptional repressors, LSF and YY-
1, have been reported to interact with the Nuc-1 region to
recruit histone deacetylase 1 (HDAC-1) to the viral promoter
and repress transcription.108 In addition to LSF and YY-1, a
number of other proteins can also recruit HDACs to different
regions of the HIV LTR. For example, the homodimer formed
by the NF-κB p50 subunit binds to the NF-κB binding sites
located in the HIV enhancer region, leading to the recruitment
of HDAC1 to the LTR and inhibition of viral transcription.109
Consistently, the RNAi-mediated p50 knockdown reduces
HDAC1 binding to the LTR, which in turn results in enhanced
recruitment of Pol II and reactivation of latent HIV in J-Lat 6.3
cells.109 Upon stimulation by the pro-inflammatory cytokine
TNF-α, the NF-κB p50/p65 heterodimer displaces the p50
homodimer and activates HIV transcription.110
As a transcriptional repressor in the Notch signaling pathway,
CBF-1 and its cofactors CIR and mSIN3A can also bind to the
NF-κB binding sites in the viral LTR and recruit HDACs.16,111
In a latency model based on primary CD4+ T cells, CBF-1,
CIR, and mSin3A, together with HDAC1 and other markers of
restrictive chromatin, were all detected on the proviral
chromatin before induction.16 The induction with the α-
CD3/CD28 antibodies substantially decreased the levels of
CBF-1, CIR, mSIN3A, and HDAC-1, but increased the level of
Pol II at the promoter. Further expanding the list of sequence-
specific transcription factors that are capable of recruiting
HDACs to the HIV LTR, both HDAC1 and HDAC2 can also
be recruited by the corepressor COUP-TF interacting protein
(CTIP2) by binding to the Sp1 elements in the LTR.108b,112
Finally, several other transcription factors such as AP-4, c-Myc,
and Sp1 can also recruit HDAC1 to the HIV-1 promoter.113
Taken together, these studies indicate the recruitment of
HDACs to the viral promoter to repress transcription and
establish latency as a common property shared by many
transcription factors that interact with the enhancer or
promoter-proximal region of the HIV LTR.
Whereas histone deacetylation contributes to the repressive
chromatin structure, acetylation of histones produces the
opposite effect. As for HIV, histone acetylation at the viral
promoter is associated with induced latency reactivation.
Various stimuli can induce the accumulation of the NF-κB
p65 subunit in the nucleus, which results in the formation of
the p50/p65 heterodimer, recruitment of cellular HATs such as
p300/CBP, PCAF, and GCN5 to the viral enhancer region,
acetylation of chromatin, improved accessibility for Pol II, and
eventually activation of HIV transcription initiation.114 The
recruitment of HATs can, in turn, stabilize NF-κB on the LTR,
as acetylation of p65 increases NF-κB’s DNA-binding
affinity.115 In addition to NF-κB, several other transcription
factors such as NFAT, GR, C/EBP, LEF-1, IRF, Ets-1, AP-1, c-
Myb, and Sp1 can also recruit HATs onto the LTR to activate
transcription initiation.114c,116 Finally, in addition to these
cellular transcription factors, HIV Tat has also been reported to
recruit p300 and PCAF to the LTR through binding to the
TAR RNA, which might further contribute to its ability to
activate the integrated provirus.114d
The initiation of HIV transcription is also repressed by
methylation of histone H3 such as di- or trimethylation on Lys9
(H3K9me2 or H3K9me3) and trimethylation on Lys27
(H3K27me3).4c,112b,117 Histone lysine methyltransferase
(HKMT) SUV39H1 is responsible for H3K9me3, which is
frequently associated with heterochromatin formation and
serves as a platform to recruit the chromodomain protein
HP1γ.117a Of note, SUV39H1 can also interact with CTIP2,
which is able to recruit HDAC1 and HDAC2 to the HIV LTR
as mentioned above. Thus, by enforcing two kinds of repressive
histone modifications of the HIV chromatin, the SUV39H1-
CTIP2 interaction cooperatively contributes to the establish-
ment of a highly repressive chromatin structure.112b Whereas
H3K9me3 is generated by SUV39H1, H3K9me2 is induced by
another HKMT called G9A. Similarly to H3K9me3, H3K9me2
also contributes to the maintenance of HIV latency as
demonstrated by the treatment with BIX01924, a specific
inhibitor targeting G9A, which caused the virus to exit
latency.117b Finally, the HKMT responsible for H3K27me3 is
a nuclear protein called EZH2, which is a component of the
polycomb repressive complex 2 (PRC2).118 Knockdown and
specific inhibition of EZH2 show that it appears to play an even
more important role in maintaining HIV latency than do
SUV39H1 and G9A and, thus, might serve as a central
regulator of HIV epigenetic silencing.118
Similarly to the methylation of histone H3 mentioned
previously, DNA methylation is also a repressive mark on the
HIV promoter and detected on cytosine residues in the two
CpG islands flanking the HIV transcription start site (TSS) in
latently infected Jurkat and primary CD4+ T cells.119 The
methyl-CpG binding domain protein 2 (MBD2) binds to the
second CpG island and recruits HDAC2 to help maintain the
repressive chromatin structure during latency.119 Inhibition of
cytosine methylation by 5-aza-2′-deoxycytidine (aza-CdR) has
been shown to abrogate the recruitment of MBD2 and
HDAC2. As such, aza-CdR can synergize with prostratin or
TNF-α to reactivate latent HIV.119 Further supporting the role
of CpG methylation in HIV latency, it has been found that, in
the latent reservoirs of HIV-infected individuals with non-
detectable plasma viremia, the HIV promoter and enhancer are
hypermethylated and resistant to reactivation, as opposed to
the hypomethylated 5′ LTR in viremic patients.120 Finally,
implicating a strong correlation between DNA methylation and
histone methylation and deacetylation in maintaining HIV
latency, a latently infected Jurkat cell line with densely
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methylated HIV promoter displays much higher level of
H3K27me3 and is more efficiently reactivated by the HDAC
inhibitor suberoylanilide hydroxamic acid (SAHA) than other
cell lines containing latent proviruses with little or no 5′ LTR
DNA methylation.120
SWI/SNF is an ATP-dependent multisubunit nucleosome-
remodeling complex with two key subunits Brg-1 and Brm that
possess ATP-dependent nucleosome remodeling activities. It
can exist in two different forms: PBAF with the defining
subunits Brd7, BAF180, and BAF200 and BAF with the
defining subunit BAF250a (ARID1a). Both forms participate in
HIV transcriptional control albeit with opposing functions:
Whereas BAF represses HIV transcription initiation by
positioning Nuc-1 downstream of the TSS,121 PBAF enhances
initiation by removing Nuc-1.96c,122 Suggesting that these two
SWI/SNF complexes of opposing activities might function at
different stages of the HIV life cycle, upon activation of HIV
transcription, BAF dissociates from the LTR region, and PBAF
is then recruited by the Lys50-acetylated Tat to the promoter
to stimulate transcription (Figure 6).121,123 In addition to
inducing a more relaxed chromatin conformation, the
acetylated histones at the HIV promoter, especially those
induced by the Tat-recruited PCAF,114d might also serve to
stabilize PBAF complex on HIV promoter through binding to
the bromodomain of PBAF’s component Brg-1.124
14. FUTURE PERSPECTIVES
Over the past 15 years or so, remarkable advances have been
made toward the elucidation of the mechanism and factors that
regulate HIV transcriptional elongation. Among these, the
identification of P-TEFb as a key host cellular cofactor for Tat
transactivation, the isolation and in-depth analyses of several P-
TEFb-containing complexes and their impact on HIV tran-
scription, and the determination of crystal structures of Tat in
complex with its key binding partners are some of the
highlights that have provided unparalleled molecular insights
into the intricate control of HIV transcription.
As expected, these advances have raised new questions even
though some of the old ones still remain unanswered. For
example, high-resolution structures of the various P-TEFb-
containing complexes are yet to be determined to reveal how P-
TEFb activity is regulated in these complexes and what triggers
P-TEFb’s transfer from one complex to the other. It is also
important to investigate whether the assembly, stability and
function of these complexes are regulated by posttranslational
modifications, of which only a small number have been
identified and studied. Moreover, structural and functional
analyses are yet to be performed to determine how HIV Tat
and TAR interact with the complete SEC and whether these
interactions present any useful therapeutic targets for
developing novel antiviral drugs. Finally, critical epigenetic
controls of the HIV chromatin and their precise roles in
contributing to the establishment, maintenance and termination
of viral latency remain to be further elucidated. Judging by the
accelerated rate of discovery in this field, answers to some of
these questions will undoubtedly be obtained within the next
few years, which will provide exciting opportunities to design
novel strategies to eradicate latent HIV reservoirs and achieve a
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